Pfizer, a pharmaceutical company listed on the New York Stock Exchange (NYSE: PFE), has received approval from the U.S. Food and Drug Administration (FDA) for LITFULOu2122 (ritlecitinib), an oral treatment taken once daily. This medication is intended for individuals aged 12 and above who have severe alopecia areata. The recommended dosage for LITFULO is 50 mg. This approval was granted on June 23, 2023.